We are building a pipeline of biologic medicines that leverage targets at the interface between the immune system and cancer, taking advantage of tumor specific characteristics and development opportunities for multiple modalities. Our anti-cancer medicines include therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Through our ongoing collaboration with the Lieping Chen lab, we have a product engine for continually evaluating and identifying promising anti-cancer targets.
The company’s lead program, NRM-823, is a T cell engager with tumor-specific targeting being developed for the treatment of multiple solid tumors and is expected to enter the clinic in 2H 2025. Our preclinical data demonstrate in vitro picomolar cell-killing and efficacy in transgenic mouse models of several cancers with no downregulation of surface protein expression. We anticipate this target may be leveraged in other biologics modalities including antibody-drug conjugate and radiotheranostics.
